Back to search results

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Recurrent Endometrial Carcinoma · Recurrent Endometrial Clear Cell Adenocarcinoma · Recurrent Endometrial Endometrioid Adenocarcinoma · Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma · Recurrent Ovarian Clear Cell Adenocarcinoma · Recurrent Ovarian Endometrioid Adenocarcinoma · Recurrent Ovarian High Grade Serous Adenocarcinoma · Recurrent Ovarian Low Grade Endometrioid Adenocarcinoma · Recurrent Platinum-Resistant Ovarian Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Augusta University Medical Center, Augusta, Georgia, United States

  • University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · cancerclinicaltrials@bsd.uchicago.edu · 773-702-8222
    Contact: Principal Investigator (Katherine C. Kurnit)

  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States

    Contact: Study coordinator (Site Public Contact) · 800-237-1225
    Contact: Principal Investigator (David P. Bender)

  • Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States

  • University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

    Contact: Study coordinator (Site Public Contact) · HSC-ClinicalTrialInfo@salud.unm.edu · 505-925-0348
    Contact: Principal Investigator (Carolyn Y. Muller)

  • Case Western Reserve University, Cleveland, Ohio, United States

  • Cleveland Clinic Foundation, Cleveland, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · TaussigResearch@ccf.org · 866-223-8100
    Contact: Principal Investigator (Peter G. Rose)

  • Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jamesline@osumc.edu · 800-293-5066
    Contact: Principal Investigator (John L. Hays)

  • University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

    Contact: Study coordinator (Site Public Contact) · ou-clinical-trials@ouhsc.edu · 405-271-8777
    Contact: Principal Investigator (Lauren E. Dockery)

  • NRG Oncology, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Fiona Simpkins) · Fiona.Simpkins@pennmedicine.upenn.edu
    Contact: Principal Investigator (Fiona Simpkins)

  • University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Site Public Contact) · PMCancerResearch@pennmedicine.upenn.edu · 215-349-8245
    Contact: Principal Investigator (Fiona Simpkins)

  • Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Site Public Contact) · ONCTrialNow@jefferson.edu · 215-600-9151
    Contact: Principal Investigator (Mitchell I. Edelson)

  • Women and Infants Hospital, Providence, Rhode Island, United States

    Contact: Study coordinator (Site Public Contact) · 401-274-1122
    Contact: Principal Investigator (Cara A. Mathews)

  • Medical College of Wisconsin, Milwaukee, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · 414-805-3666
    Contact: Principal Investigator (William H. Bradley)
Study leads

  • Fiona Simpkins

    Principal Investigator

    NRG Oncology

View source on ClinicalTrials.gov(opens in a new tab)